Lilly and Incyte Report Results of Baricitinib in P-III COV-BARRIER Study for Hospitalized Patients with COVID-19
Shots:
- The P-III COV-BARRIER study evaluating Baricitinib (4 mg- qd) + SoC (corticosteroids- antimalarials- antivirals- azithromycin) vs PBO + SoC in 1525 patients hospitalized with COVID-19. The patients treated with baricitinib in addition to SoC includes 79% receiving corticosteroids and 19% receiving remdesivir- with some receiving both
- The trial did not meet 1EPs i.e. showed a 38% reduction in mortality by Day 28- non-invasive mechanical ventilation at baseline (17.5% vs 29.4%)
- Lilly plans to publish the data in a peer-reviewed journal in the coming mos. and share the data with regulatory authorities in the US- EU- and other geographies
Ref: Incyte | Image: Wikipedia
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com